4.7 Review

The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma

期刊

出版社

MDPI
DOI: 10.3390/ijms231810279

关键词

PDAC; targeted strategies; GPC1; monoclonal antibodies; immunotherapy; nanoparticles; chitosan

资金

  1. Italian Ministry of Health (Ricerca Corrente)

向作者/读者索取更多资源

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, with low survival rates and a majority of patients already in advanced stages. Current treatment options for PDAC are limited, highlighting the need for targeted therapies that can differentiate between cancerous and non-cancerous cells. Antibody-based immunotherapies and antibody-conjugated nanoparticle-based targeted therapies, targeting specific tumor-associated antigens (TAA), show promise as potential innovative treatments.
Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of all pancreatic cancers, with a 5-year survival rate of 7% and 80% of patients diagnosed with advanced or metastatic malignancies. Despite recent advances in diagnostic testing, surgical techniques, and systemic therapies, there remain limited options for the effective treatment of PDAC. There is an urgent need to develop targeted therapies that are able to differentiate between cancerous and non-cancerous cells to reduce side effects and better inhibit tumor growth. Antibody-targeted strategies are a potentially effective option for introducing innovative therapies. Antibody-based immunotherapies and antibody-conjugated nanoparticle-based targeted therapies with antibodies targeting specific tumor-associated antigens (TAA) can be proposed. In this context, glypican-1 (GPC1), which is highly expressed in PDAC and not expressed or expressed at very low levels in non-malignant lesions and healthy pancreatic tissues, is a useful TAA that can be achieved by a specific antibody-based immunotherapy and antibody-conjugated nanoparticle-based targeted therapy. In this review, we describe the main clinical features of PDAC. We propose the proteoglycan GPC1 as a useful TAA for PDAC-targeted therapies. We also provide a digression on the main developed approaches of antibody-based immunotherapy and antibody-conjugated nanoparticle-based targeted therapy, which can be used to target GPC1.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据